Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Genprex, Inc. entered into Purchase Agreement with accredited healthcare-focused institutional investors valued at approximately $6.7 million (effective 2023-07-18).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- accredited healthcare-focused institutional investors
- Value
- approximately $6.7 million
- Effective
- 2023-07-18
Exact text from the filing
On July 18, 2023, Genprex, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with accredited healthcare-focused institutional investors (the “Purchasers”) pursuant to which the Company agreed to issue and sell to the Purchasers, in a registered direct offering (the “Offering”) priced at the market under Nasdaq rules, an aggregate of (i) 7,425,744 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) warrants (the “Warrants”) exercisable for up to an aggregate of 7,425,744 shares of Common Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Genprex, Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC.
- Action
- entry
- Agreement
- underwriting
- Counterparty
- H.C. Wainwright & Co., LLC
Exact text from the filing
Pursuant to an Engagement Letter (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (the “Placement Agent”), the Company agreed to pay the Placement Agent in connection with the Offering (i) a cash fee equal to 7.0% of the aggregate gross proceeds received in the Offering, (ii) a management fee equal to 1.0% of the aggregate gross proceeds of the Offering, (iii) $50,000 for fees and expenses of the Placement Agent’s counsel and other out of pocket expenses, (iv) a non-accountable expense allowance of $25,000 and (v) $15,950 for the clearing expenses.
View on SEC.gov